Company intelligence / Profile preview

Motif Neurotech

Houston, Texas, United Statesmotifneuro.tech ↗

Ownership: Private
Development stage: Phase 1

Overview

Motif Neurotech has developed the DOT microstimulator, a miniature, wireless, battery-free brain implant designed to stimulate the prefrontal cortex for treatment-resistant depression. The device has completed first-in-human proof-of-concept implantation and large animal studies demonstrating safety and ability to deliver targeted neurostimulation. Clinical trials of chronic implants are planned for 2025[6][8].

Therapeutic areas: Psychiatry
Modalities: DeviceBioelectronic therapyNeuromodulation
Industry: Implantable Medical Devices

Drug pipeline

1 asset

DOT

Phase 1

Indications: Treatment-resistant depression

Partnerships

Rice University (technology originator/founder collaboration)MintNeuro (for Brain Mesh IC development)

Beyond the preview

Go deeper on Motif Neurotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Motif Neurotech.

Explore the full profile